Recruiting

ICG-Guided PDT

Sponsor:

Manhattan Eye, Ear & Throat Hospital

Code:

NCT01974622

Conditions

Retinal Vascular Disorders

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Interventions

Visudyne

Study Details

Brief summary:

The purpose of this research is to use an approved drug(Visudyne) for neovascular age-related macular degeneration, which is essentially choroidal neovascularization for permeability and vascular proliferation for the retinal circulation, to treat another permeable abnormality - retinal capillary abnormalities - located eccentric to the central portion of the macula or in the foveal region.

Conditions

Retinal Vascular Disorders

Study ID

NCT01974622

Start date

Apr, 2013

Status verified date

Oct, 2013

Completion date

Jun, 2015

Anticipated

Primary completion date

Jun, 2015

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Inclusion Criteria:• Individuals that are 50 years of age and older.

  • Patients with retinal capilary abnormalities/vascular diseases such as macular telangiectasia type I and type II, retinal arteriolar macroanurysms, and retinal angiomous proliferation (RAP).
  • Patients with diabetic retinopathy and branch retinal vein occlusions
  • Other patients who are non-responders to approved treatment methods

Exclusion Criteria:

  • Patients whose diseases have approved methods of treatment.
  • Pregnant women or women of normal child bearing age.

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Visudyne

Visudyne half fluence- 1 treatment with the possibility of a second treatment.

Interventions

Visudyne

Half fluence verteporfin

Primary outcome measure

  • Improvement and/or stabilization of disease. [ Time Frame: 1-2 years ]

Central Contacts and Locations

Locations

Vitreous Retina Macula Consultants of New York

Recruiting

New York, New York, United States, 10022

Contacts

Lawrence A. Yannuzzi, M.D.

212-605-3777layannuzzi@gmail.com

Irene Barbazetto, M.D.

(212) 861-9797ibarbazetto@gmail.com

Principal Investigator:

Lawrence A. Yannuzzi, M.D.

More Information

Sponsor

Manhattan Eye, Ear & Throat Hospital

Last update posted

Nov 1, 2013

Last verified

Oct, 2013

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Manhattan Eye, Ear & Throat Hospital on 2013-11-01.